scholarly journals Causes and Stages of Hepatocellular Carcinoma at Patient Presentation at a Tertiary Medical Center in Western Saudi Arabia

2014 ◽  
Vol 05 (14) ◽  
pp. 1303-1310 ◽  
Author(s):  
Shadi Alkhayyat ◽  
Hind I. Fallatah ◽  
Hisham O. Akbar ◽  
Mahmoud S. Al Ahwal ◽  
Waleed S. Al Ghamdi
Keyword(s):  
Hepatocellular Carcinoma ◽  
Saudi Arabia ◽  
Medical Center ◽  
Patient Presentation

scholarly journals Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea

Liver Cancer ◽  
2021 ◽  
pp. 1-11
Author(s):  
Myung Ji Goh ◽  
Joo Hyun Oh ◽  
Yewan Park ◽  
Jihye Kim ◽  
Wonseok Kang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factors ◽  
Disease Progression ◽  
Real World ◽  
Medical Center ◽  
Objective Response ◽  
Progression Free Survival ◽  
Efficacy And Safety ◽  
Eligibility Criteria ◽  
Unresectable Hepatocellular Carcinoma

<b><i>Background:</i></b> Lenvatinib has been recently approved as a first-line treatment option for patients with unresectable hepatocellular carcinoma (HCC) in Korea. We aimed to study the efficacy and safety of lenvatinib therapy in a real-world practice and to find prognostic factors related to survival and disease progression. <b><i>Methods:</i></b> A hospital-based retrospective study was conducted on 111 consecutive patients who had unresectable HCC and were treated with lenvatinib at Samsung Medical Center from October 2018 to March 2020. Efficacy was determined using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria in 111 patients who completed 1st tumor assessment. Safety was evaluated in 116 HCC patients including 5 patients who discontinued lenvatinib due to adverse events (AEs) before 1st tumor assessment using Common Terminology Criteria for AEs version 5.0. <b><i>Results:</i></b> A total of 111 patients with a median age of 59 years were analyzed during a median follow-up duration of 6.2 (4.4–9.0) months. The Kaplan-Meier estimate of overall survival was 10.5 months, and the median progression-free survival was 6.2 months. Based on mRECIST criteria, the objective response rate was 18.9% and disease control rate was 75.7%. AEs developed in 86/116 (74.1%) patients, and grade ≥3 AEs developed in 16/116 (13.8%) patients. Diarrhea, hand-foot skin rash, abdominal pain, hypertension, and anorexia were identified as the AEs with the highest frequencies of any grade. REFLECT eligibility criteria including tumor extent ≥50% liver occupation or inadequate bone marrow function and occurrence of anorexia were prognostic factors for survival, and occurrence of diarrhea was a favorable factor for disease progression. <b><i>Conclusion:</i></b> Lenvatinib therapy showed a favorable efficacy and safety in a real-world practice. The REFLECT eligibility criteria and specific AEs could be one of the prognostic markers.

scholarly journals The impact of COVID 19 pandemic on pattern of cancer mortality in Najran, Saudi Arabia: a single-cancer center experience

2021 ◽  
Author(s):  
Ahmed M Badheeb ◽  
Mohamed A Badheeb ◽  
Hamdi A Alhakimi
Keyword(s):  
Hepatocellular Carcinoma ◽  
Saudi Arabia ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Cancer Mortality ◽  
Cancer Center ◽  
Anti Cancer ◽  
Before And After ◽  
The Difference ◽  
The Impact

Abstract Background: The aim of this paper is to compare the patterns and determinants of cancer mortality in Najran region before and after the COVID-19 epidemics. The association between cancer mortality and each of age, sex, site of cancer, stage, and the 30-days survival rate after the last dose of chemotherapy were assessed.Materials & Methods: Adult cancer patients who died of cancer in King Khalid Hospital in Najran Saudi Arabia, were included in this retrospective observational study. We compared mortality patterns in a period of 6 months in 2020 (March to August) with the corresponding period of 2019.Results: 50 dead adult cancer patients were included, 24 in 2019 and 26 in 2020. Among them, 21% vs 42% were younger than 65 years of age; 61% vs 62% were males, for the years 2019 & 2020 respectively. The top three killers in 2019 were colorectal, gastro-esophageal cancers, and hepatocellular carcinoma, while in 2020 were colorectal, hepatocellular carcinoma, and lymphomas. About 16.7% of patients died within 30 days of receiving anti-cancer treatment in 2019 in comparison with 7.7% in 2020. The difference in the 30-days mortality after receiving anti-cancer treatment was not statistically significant between 2019 and 2020 (p = 0.329).Conclusion: The Year 2020, the time of the COVID-19pandemic, was not associated with a significant increase in short-term mortality among patients with malignancy in Najran, Saudi Arabia. Our results generally reflect the crucial role of strict preventive national measures in saving lives and warrants further exploration.

Stereotactic Body Radiation Therapy as a Salvage Treatment for Single Viable Hepatocellular Carcinoma at the Site of Incomplete Transarterial Chemoembolization

2021 ◽  
Author(s):  
Sumin Lee ◽  
Jinhong Jung ◽  
Jin-hong Park ◽  
So Yeon Kim ◽  
Jonggi Choi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Adverse Events ◽  
Transarterial Chemoembolization ◽  
Stereotactic Body Radiation Therapy ◽  
Medical Center ◽  
Salvage Treatment ◽  
Iodized Oil ◽  
Stereotactic Body Radiation

Abstract Background: To evaluate the clinical outcomes of patients who received stereotactic body radiation therapy (SBRT) for single viable hepatocellular carcinoma (HCC) at the site of incomplete transarterial chemoembolization (TACE).Methods: Incomplete TACE was defined as (1) evidence of viable HCC at the site of TACE on follow-up images following one or more consecutive TACEs, (2) no definite tumor staining on celiac angiogram, or (3) no definite iodized oil uptake on post-embolization angiogram or computed tomography. A total of 302 patients were treated between 2012 and 2017 at Asan Medical Center (Seoul, South Korea). Doses of 10–15 Gy per fraction were given over 3–4 consecutive days. Treatment-related adverse events were evaluated according to the common terminology criteria for adverse events, version 4.03.Results: The median follow-up duration was 32.9 months (interquartile range [IQR], 23.6–41.7) and the median tumor size was 2.0 cm (range, 0.7–6.9). The local control (LC) and overall survival rates at 3 years were 91.2% and 72.7%, respectively. 95.4% of the tumors reached complete response (CR) during the entire follow-up period (anyCR). The median interval from SBRT to anyCR was 3.4 months (IQR, 1.9–4.7), and 39.9% and 83.3% of the lesions reached CR at 3- and 6-months after SBRT, respectively. Radiation-induced liver disease was observed in 8 (2.6%) patients. No patients experienced gastroduodenal bleeding within the radiation field.Conclusion: SBRT should be considered a feasible salvage treatment option for HCC after incomplete TACE.

Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center

2019 ◽  
Vol 51 (3) ◽  
pp. 972-979
Author(s):  
Brian Rutledge ◽  
Jenny Jan ◽  
Sindhuri Benjaram ◽  
Neha Sahni ◽  
Paul Naylor ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
African American ◽  
Medical Center ◽  
Racial Diversity ◽  
American Population ◽  
African American Population

scholarly journals Repeated CyberKnife stereotactic body radiation therapy in hepatocellular carcinoma

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Jing Sun ◽  
Can Ouyang ◽  
Xiaoyun Chang ◽  
Aimin Zhang ◽  
Quan Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Medical Center ◽  
Survival Rates ◽  
Progression Free Survival ◽  
Interval Time ◽  
Stereotactic Body Radiation ◽  
Kaplan Meier ◽  
Radiation Induced

Abstract Background To explore the survival and side effects of repeated CyberKnife stereotactic body radiation therapy (CK-SBRT) on hepatocellular carcinoma patients. Methods 24 HCC patients were collected at The Fifth Medical Center of PLA General Hospital from November 2011 to July 2016. They received second-course CK-SBRT with a prescribed dose of 50(48–55) Gy/5-8fx, and a single dose of 10 (7–11) Gy/fx. Cumulative overall survival rates (OS), progression-free survival rates (PFS) and local control rates (LC) were calculated by Kaplan-Meier method. Results All patients finished their radiotherapy plans. The 1-,2- and 3-year cumulative OS rate were 95.8,81.1 and 60.8%. The 1-,2- and 3-year LC rate were 95.5,90.7 and 90.7%, respectively. The 1-, 2- and 3-year PFS were 74.8, 49.2 and 39.4%, respectively. 16 patients complained of fatigue during second-course therapy, 2 patients showed Grade 2 gastrointestinal reaction, 1 patient was diagnosed radiation-induced liver disease and none died. PFS was significantly higher in the interval time < 12 months group than in the interval time ≥ 12 months group (p = 0.030). Conclusions It is preliminarily believed that re-CK-SBRT is an effective and safe treatment for HCC patients, but the treatment criteria should be strictly controlled.

scholarly journals Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: Analysis of 5,613 cases from a medical center in southern Taiwan

2007 ◽  
Vol 120 (12) ◽  
pp. 2650-2655 ◽  
Author(s):  
Kwong-Ming Kee ◽  
Jing-Houng Wang ◽  
Chuan-Mo Lee ◽  
Chao-Long Chen ◽  
Chi-Sin Changchien ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Medical Center ◽  
Staging System ◽  
Tnm Staging ◽  
Tnm Staging System ◽  
Southern Taiwan

Survival analysis of Hispanics with hepatocellular carcinoma at a large academic institution.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14682-e14682
Author(s):  
Daniel Lin ◽  
Andreas Kaubisch ◽  
Sanjay Goel ◽  
Yungtai Lo ◽  
Santiago Aparo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cancer Registry ◽  
Medical Center ◽  
Tumor Stage ◽  
The United States ◽  
Academic Institution ◽  
Age At Diagnosis ◽  
Protein Levels ◽  
Montefiore Medical ◽  
Alpha Feto Protein

e14682 Background: Hepatocellular carcinoma (HCC) appears to have worse prognosis among Hispanics in the United States who have a higher mortality when compared toBlacks and Non-Hispanic Whites based on statistics from the Surveillance Epidemiology and End Results (SEER) database. There is paucity of data directly comparing Hispanics vs. Non-Hispanics. The aim of this study is to compare the overall survival (OS) of Hispanics and Non-Hispanics with HCC at a large academic institution. Methods: Men and women diagnosed and treated for HCC at Montefiore Medical Center (MMC) from 2000 to 2009 were identified using data from the MMC Cancer Registry. Patient’s characteristics obtained included age at diagnosis, gender, race, tumor stage, Model for End-stage Liver Disease (MELD) scores, Hepatitis B, C and HIV status, alcohol use, presence of cirrhosis, alpha-feto protein levels, performance status and treatment. A Cox proportional-hazard model was used to assess survival differences between Hispanics and Non-Hispanics adjusting for clinically relevant and statistically significant variables. Results: A total of 513 patients were identified from the Cancer Registry database. 76 patients were excluded (58 due to inability to confirm the diagnosis of HCC based on current radiologic criteria, 18 due to unavailable ethnicity data). The remaining 437 patients were used for modeling and final analysis. Of the final cohort of 437 patients, 49% (n=212) were Hispanic and 51% (n=225) were Non-Hispanic. Among Non-Hispanics, 55% were Black, 35% were White and 10% were “other” race. Median time of follow up for Hispanics was 13.5 months and for Non-Hispanics was 12.1 months. The median OS among Hispanics was 14.5 months and was not statistically different from the Non-Hispanic group (median OS of 13.1 months) with a p value of 0.49. In a multivariate analysis model the hazard ratio (HR) for survival among Hispanics was 0.81 (95% CI 0.61 to 1.07, p= 0.15) when compared to Non-Hispanics; after adjusting for gender, age at diagnosis, tumor stage, treatment, alpha-feto protein levels and MELD scores. Conclusions: Hispanics diagnosed and treated with HCC at Montefiore Medical Center do not seem to have worse survival when compared to Non-Hispanics.

Sign in / Sign up

Export Citation Format

Share Document